Current Oncology, Free Full-Text

Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.

Oncology Times, November 5, 2020 Vol.42 Issue 21

Prioritising breast cancer theranostics: A current medical longing

Current Oncology, Free Full-Text

Current Oncology, Free Full-Text

Current Oncology, Free Full-Text

7th Singapore Society of Oncology Annual Scientific Meeting 2022 – Malaysian Oncological Society

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Pallimed: 07_05

PPT - Carefully Coding Radiation Oncology PowerPoint Presentation

Free webinar today: How is NGS informing oncology drug discovery

Current Oncology, Free Full-Text

Current Oncology, Free Full-Text

Current Oncology, Free Full-Text, bronstein méier resultado